Physician

Khaleel K Ashraf, M.D.

According to 2025 Medicare claims, Khaleel Ashraf, M.D. (NPI: 1760437925) practices hematology/oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is HEMATOLOGY AND ONCOLOGY ASSOCIATES OF ALABAMA, LLC (NPI: 1134232770; TIN: 631137578) and primary practice location at 35209-6862.

Ashraf's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 418 traditional Medicare patients, billed 83,421 HCPCS/CPT codes, and received $2,437,504 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,761 prescription claims across 354 beneficiaries totaling $4,624,087 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 61 claims. Open Payments data shows 273 records totaling $45,932. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,012,276 to $2,437,504. Similarly, Part D prescription costs have risen steadily, from $2,838,514 to $4,624,087. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $6,649 and ending at $3,707.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	502	45,586	$1,012,276
2016	511	84,662	$1,538,518
2017	431	84,094	$1,670,632
2018	449	138,986	$2,433,538
2019	466	138,270	$2,576,389
2020	416	124,551	$2,178,298
2021	476	103,272	$1,979,153
2022	359	82,384	$1,961,709
2023	388	93,382	$2,129,255
2024	418	83,421	$2,437,504

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	259	2,701	$2,838,514
2016	259	2,587	$2,824,575
2017	257	2,296	$2,133,289
2018	267	2,365	$2,446,742
2019	286	2,244	$2,960,668
2020	253	2,296	$2,762,383
2021	325	2,514	$2,773,650
2022	265	2,367	$3,316,328
2023	268	2,310	$3,657,569
2024	354	2,761	$4,624,087

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	118	$28,667
2016	N/R	112	$79,874
2017	N/R	134	$20,181
2018	N/R	60	$2,385
2019	N/R	15	$1,331
2020	N/R	14	$1,221
2021	N/R	49	$3,343
2022	N/R	92	$66,267
2023	N/R	108	$77,094
2024	N/R	61	$74,116

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	277	517	$85
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	108	389	$43
96375	Injection of additional new drug or substance into vein	61	784	$11
36415	Insertion of needle into vein for collection of blood sample	273	793	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	286	1,062	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	28	784	$454,232
Jakafi	Ruxolitinib Phosphate	25	750	$412,705
Xtandi	Enzalutamide	28	840	$387,447
Verzenio	Abemaciclib	30	840	$367,506
Lonsurf	Trifluridine/Tipiracil Hcl	12	336	$223,139

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$38,346
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	12	$27,808
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	23	$7,582
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$380

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	270	$34,385	GlaxoSmithKline, LLC.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$11,547	Novocure GmbH
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Khaleel K. Ashraf, M.D.?

Tedicare shows public-source Medicare data for Khaleel K. Ashraf, M.D. (NPI 1760437925), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Khaleel K. Ashraf, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Khaleel K. Ashraf, M.D.?

Khaleel K. Ashraf, M.D. is linked to HEMATOLOGY AND ONCOLOGY ASSOCIATES OF ALABAMA, LLC (billing NPI 1134232770) in the available physician profile data.

Does Khaleel K. Ashraf, M.D. have Open Payments data?

Khaleel K. Ashraf, M.D. has 273 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.